Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
ASSETS
Cash and cash equivalents
Investments
Accounts receivable
Prepaid expenses
Income taxes receivable
Property and equipment, net of depreciation
Deferred taxes
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Liabilities
Accounts payable and accrued expenses
Accrued incentive compensation
Income taxes payable
Lease liability
Deferred compensation
Total liabilities
Redeemable noncontrolling interest
Permanent Shareholders’ Equity
Common shares, no par value: 7,000,000 shares authorized; 2,705.580 issued and outstanding at December 31, 2025 (inclusive of 274,349 unvested shares); 2,670,469 issued and outstanding at December 31, 2024 (inclusive of 173,120 unvested shares)
Preferred shares, undesignated: 1,000,000 shares authorized and unissued
Deferred equity compensation
Retained earnings
Total permanent shareholders’ equity
Total liabilities and shareholders’ equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support